14th Apr 2015 07:47
LONDON (Alliance News) - Cyprotex PLC Tuesday said it has launched a new in-vitro service to identify potential cardiotoxic liabilities of pharmaceuticals, using 3D cell culture methods and confocal high-content imaging technology.
Cyprotex, a specialist ADME-Tox contract research organisation, said the 3D microtissues are formed from a co-culture of three different types of cardiac cells present in the heart. Using this method, the cells are able to beat spontaneously in a similar manner to a human heart, it said.
Confocal high content imaging technology uses fluorescent dyes to stain particular regions of the cell to identify changes in response to increasing doses of pharmaceutical drugs. Using this technology, Cyprotex's research shows that the new 3D microtissue model is able to accurately identify drugs which cause structural damage to the heart.
"Drug-induced cardiovascular toxicity is the leading cause of attrition during drug development. Our expertise in the field of in-vitro toxicology has enabled us to develop a highly predictive and sophisticated model for correctly identifying cardiotoxicity which can be applied at an early stage of the drug development process," Chief Executive Anthony Baxter said in a statement.
Shares in Cyprotex were untraded Tuesday morning, last trading at 55.10 pence each.
By Karolina Kaminska; [email protected] @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
CRX.L